5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia

    John D. McCoy, Flavio A. Cadegiani, Carlos Gustavo Wambier … Andy Goren
    Studysummary This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign Journal of The American Academy of Dermatology · 2020
    2. Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign' Journal of The American Academy of Dermatology · 2020
    3. A Preliminary Observation: Male Pattern Hair Loss Among Hospitalized COVID-19 Patients in Spain – A Potential Clue to the Role of Androgens in COVID-19 Severity Journal of Cosmetic Dermatology · 2020
    4. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor ˜The œJournal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism · 2004

    Related research 1

    1. Effects of 5-Alpha Reductase Inhibitors on Lung Function: A Reason for Discontinuation During COVID-19 Pandemic? Dermatologic Therapy · 2020